Skip to main content
. 2022 May 26;11(23):4491–4500. doi: 10.1002/cam4.4834

FIGURE 3.

FIGURE 3

The effects of ALK TKIs on different ALK fusions and variants. The distribution of ALK fusion types (A) and EML4‐ALK variants (D); PFS comparison between subgroups of patients with different ALK fusions: EML4 group and non‐EML4 group in crizotinib cohort (B) and alectinib cohort (C); (E and F) PFS comparison between subgroups of patients with different EML4‐ALK variants: v1 versus others in crizotinib cohort (E) and alectinib cohort (F).